AstraZeneca’s (AZN) Overweight Rating Reiterated at JPMorgan Chase & Co.

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reiterated by equities research analysts at JPMorgan Chase & Co. in a research report issued on Wednesday,Digital Look reports.

AZN has been the subject of a number of other reports. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Thursday, November 7th. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 140 ($1.77) price objective on shares of AstraZeneca in a research note on Monday, January 27th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of GBX 7,542.80 ($95.15).

AstraZeneca Stock Performance

AstraZeneca stock traded down GBX 28 ($0.35) during mid-day trading on Wednesday, reaching £117.60 ($148.35). 24,679,291 shares of the company were exchanged, compared to its average volume of 27,183,740. The firm has a market cap of £226.27 billion, a PE ratio of 32.23, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The firm’s 50-day simple moving average is £109.29 and its two-hundred day simple moving average is £114.68. AstraZeneca has a twelve month low of GBX 9,670 ($121.99) and a twelve month high of £133.88 ($168.89). The company has a debt-to-equity ratio of 73.83, a quick ratio of 0.59 and a current ratio of 0.93.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.